MedPath

A comparison between the efficacy and tolerability of topical sertaconazole and topical terbinafine in localized fungal infections of the ski

Phase 4
Completed
Conditions
Health Condition 1: null- Localized epidermal dermatophytosis (epidermomycosis)
Registration Number
CTRI/2014/09/005029
Lead Sponsor
R G Kar Medical College and Hospital Kolkata
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
194
Inclusion Criteria

1. Patients aged between 18-65 years

2. Patients of both sexes

3. Patients capable of giving informed consent

4. Patients with localized epidermal dermatophytosis confirmed by presence of fungal hyphae in KOH (potassium hydroxide) preparation of skin scrapings from over the lesion at baseline visit

Exclusion Criteria

1. Patients with underlying immunosuppression

2. Pregnant or lactating women

3. Secondarily infected or eczematized lesions

4. Lesions over multiple anatomical regions

5. Lesions with nail or scalp involvement

6. Patients who received any type of anti-fungal therapy within 30 days prior to baseline visit

7. Patients who applied any other topical agent over the lesions prior to baseline visit

8. Patients incapable of understanding the protocol

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Complete clinical cure defined as complete absence of erythema, scaling and pruritus and overall global assessment. <br/ ><br>2. Mycological cure defined as absence of fungal hyphae in KOH preparation of skin scrapings from over the lesion.Timepoint: 2 and 4 weeks after randomization
Secondary Outcome Measures
NameTimeMethod
ocal adverse effects such as dryness, irritation, eczema, tenderness.Timepoint: 2 and 4 weeks after randomization;Scores of erythema, pruritus, scalingTimepoint: baseline, 2 and 4 weeks after randomization
© Copyright 2025. All Rights Reserved by MedPath